Featuring a slide presentation and related discussion from Prof Martin Reck, including the following topics:

• Overview of small cell lung cancer (SCLC) (0:00)
• First-line chemoimmunotherapy for extensive-stage SCLC (ES-SCLC) (3:50)
• Lurbinectedin as first-line maintenance therapy for ES-SCLC (12:36)
• Case: A man in his early 60s with ES-SCLC receives first-line atezolizumab/carboplatin/etoposide followed by maintenance lurbinectedin/atezolizumab (18:46)
• Case: A woman in her mid 70s with ES-SCLC experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (21:21)

CME information and select publications

Featuring an interview with Prof Martin Reck, including the following topics:

• Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)
• Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)
• Considerations with maintenance therapy for ES-SCLC (9:31)
• Considerations with immunotherapy for ES-SCLC (13:12)
• Curability of SCLC with systemic therapy (15:17)
• Data with chemoimmunotherapy for patients with poor performance status (25:55)
• Future developments in therapy for SCLC (30:11)
• Rapid fire: Small Cell 101 (35:45)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

• Introduction (0:00)
• Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
• Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

CME information and select publications